Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S GillisA Polliack

Abstract

Therapy-related acute myeloid leukemia (t-AML) is a recognized entity complicating successful therapy for Hodgkin's disease (HD) and other neoplasias after many years. This risk appears to be related to cumulative exposure to alkylating agents and procarbazine, while drugs affecting DNA--topoisomerase II, such as epipodophyllotoxins and anthracyclines, are also associated with t-AML developing after a much shorter latent period. Of 56 patients with t-AML or myelodysplasia seen in our institutes during the period 1980-1994 we encountered 5 patients with acute promyelocytic leukemia (APL) all of whom had t(15;17). Four of these had been treated for HD with both chemotherapy and radiotherapy, and one with radiotherapy alone. To the best of our knowledge these appear to be the first cases of t-AML in HD with cytogenetically proven t(15;17). Similarly to other cases of t-APL reported after therapy for neoplasias other than HD, these patients also have a relatively favorable prognosis as seen in de-novo APL. Although rare, t-APL should be added to the list of late complications of therapy for HD.

Citations

May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M BeaumontP Fenaux
May 15, 2003·Hematology·Vikas GuptaArmand Keating
Sep 19, 2000·Genes, Chromosomes & Cancer·A S QuinaL Parreira
Sep 28, 2000·Cancer Treatment Reviews·A NgO B Eden

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.